Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Gastroenterology · Lancet Gastroenterol Hepatol · 2026-08-25

In 342 patients with untreated unresectable hepatocellular carcinoma, adding atezolizumab plus bevacizumab to on-demand TACE lengthened median TACE-PFS (11.3 vs 7.0 months; HR 0.71). Overall survival, immature at interim analysis, showed no difference (HR 0.96).

RCTn = 342
Kudo et al. On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.